Reassessing the Clinical Interpretation of Atezolizumab Plus Bevacizumab in Child‐Pugh B Hepatocellular Carcinoma

Authors

Shengze Li (ORCID: https://orcid.org/0000-0003-2160-8675)
Yunyang Xu (ORCID: https://orcid.org/0000-0002-8180-2165)
Ze Xiang (ORCID: https://orcid.org/0000-0002-0897-4550)
Jian Wu

Institutions

Suzhou Municipal Hospital (CN)
Zhejiang University (CN)

Publication Details

Journal: Liver International
Published: 2026-01-05
DOI: https://doi.org/10.1111/liv.70510
Citations: 1
Primary Topic: Hepatocellular Carcinoma Treatment and Prognosis
Type: article
Field-Weighted Citation Impact: 23.38

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Reassessing the Clinical Interpretation of Atezolizumab Plus Bevacizumab in Child‐Pugh B Hepatocellular Carcinoma

Shengze Li, Yunyang Xu, Ze Xiang, Jian Wu

Jan 5, 2026

1 citations

Liver International

Hepatocellular Carcinoma Treatment and Prognosis

23.38

article

Reassessing the Clinical Interpretation of Atezolizumab Plus Bevacizumab in Child‐Pugh B Hepatocellular Carcinoma

Shengze Li, Yunyang Xu, Ze Xiang, Jian Wu

January 5, 2026article en

1 citations

Abstract

No abstract available for this paper.

Liver InternationalVol. 46(2)

Suzhou Municipal Hospital (CN), Zhejiang University (CN)

Peace, Justice and strong institutions

Openalex Percentile: Top 3%

Hepatocellular Carcinoma Treatment and Prognosis

23.38

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.